Despite recent therapeutic advances, multiple myeloma (MM) remains largely incurable. Here we report results of a phase I/II trial to evaluate the safety and activity of autologous T cells engineered to express an affinity-enhanced T cell receptor (TCR) recognizing a naturally processed peptide shared by the cancer-testis antigens NY-ESO-1 and LAGE-1. Twenty patients with antigen-positive MM received an average 2.4 × 10 9 engineered T cells 2 d after autologous stem cell transplant. Infusions were well tolerated without clinically apparent cytokine-release syndrome, despite high IL-6 levels. Engineered T cells expanded, persisted, trafficked to marrow and exhibited a cytotoxic phenotype. Persistence of engineered T cells in blood was inversely associated with NY-ESO-1 levels in the marrow. Disease progression was associated with loss of T cell persistence or antigen escape, in accordance with the expected mechanism of action of the transferred T cells. Encouraging clinical responses were observed in 16 of 20 patients (80%) with advanced disease, with a median progression-free survival of 19.1 months. NY-ESO-1-LAGE-1 TCR-engineered T cells were safe, trafficked to marrow and showed extended persistence that correlated with clinical activity against antigen-positive myeloma.
Allogeneic stem cell transplants can eradicate myeloma through the T cell-mediated 'graft-versus-myeloma' (GVM) effect, but their success is limited by morbidity and mortality from infections and organ toxicity. Autologous stem cell transplantation (ASCT) is less toxic but rarely curative, owing in part to the lack of GVM effect 1-6 . Better clinical outcomes following ASCT for myeloma are associated with rapid post-transplant lymphocyte recovery 7, 8 . Tumor-reactive T cells present at low frequencies in the marrow and blood of patients with myeloma have the potential to target myeloma cells upon activation 9, 10 . Thus, autologous immune-mediated control of myeloma may be possible.
We and others have studied whether cancer vaccines and autologous T cell transfer administered after ASCT could enhance immune reconstitution and improve post-transplant clinical outcomes in myeloma [11] [12] [13] [14] [15] [16] . A key problem with these approaches, however, is that post-transplant tumor responses remain inadequate. A probable reason for this is that tumor antigens are typically self-antigens, which would lead to deletion of high-affinity T cells capable of recognizing effective tumor antigens during the process of thymic maturation 17, 18 . Moreover, advanced cancers are often immune edited, resulting in reduced antigen presentation and thus rendering low-affinity T cells incapable of tumor interaction 19, 20 . Synthetic biology may help to overcome these problems by enabling the genetic engineering of autologous T cells to express either chimeric antigen receptors (CARs) or affinity-enhanced TCRs that recognize known tumor target antigens. Early clinical results using CAR-modified T cells have been encouraging but also highlight the risks from cytokine-release syndrome (CRS) [21] [22] [23] .
TCR-engineered T cells have been employed in a number of early-stage clinical trials for melanoma 24, 25 , although the very short-term expression (usually <1 month) of these transgenic TCRs probably compromised their clinical impact 26 . We generated NY-ESO c259 , a human-derived affinity-enhanced TCR that recognizes the NY-ESO-1-and LAGE-1-derived SLLMWITQC peptide in complex with human leukocyte antigen (HLA) serotype HLA-A*0201, as previously described 27, 28 and clinically tested in patients with metastatic synovial cell sarcoma and melanoma 29, 30 . NY-ESO-1 is an immunogenic cancer-testis antigen (CTA) associated with spontaneous and vaccine-induced immunity that can lead to clinical cancer responses 31, 32 . Up to 60% of advanced myelomas have been reported to express NY-ESO-1, a feature correlated to tumor proliferation and high-risk features [33] [34] [35] [36] [37] . We hypothesized that adoptive transfer of NY-ESO c259 TCR-engineered T cells (hereafter referred to as NY-ESO c259 T cells) would improve the duration and depth of post-ASCT clinical responses in HLA-A*0201-positive patients with advanced NY-ESO-1-and LAGE-1-expressing MM.
Our results indicate that engineered cells achieved long-term engraftment, trafficked to tumor sites and retained polyfunctionality and cytotoxic potential over time, despite the lack of systemic IL-2 administration used in prior studies with this TCR 29, 30 . The temporal pattern of tumor regression, the relationship between disease relapse and loss of T cell persistence or target antigen and the robust IL-6 production at the peak of T cell expansion we observed provide evidence of bioactivity of NY-ESO c259 T cells in vivo.
RESULTS Patients
A flow diagram depicting the trial design is shown in Figure 1 , and a consort diagram is provided in Supplementary Figure 1 . We screened HLA-A*0201-positive patients for expression of NY-ESO-1 and/or LAGE-1 in myeloma cells.
One-third (34%) of the patients screened expressed NY-ESO-1 and/or LAGE-1 mRNA, as assessed by PCR, and were therefore eligible for enrollment. LAGE-1 expression frequency was approximately twice that of NY-ESO-1. All patients had symptomatic myeloma with active disease, representing an advanced-stage population; 5 (25%) had undergone prior ASCT and 12 (60%) had cytogenetic abnormalities, including 7 (35%) categorized as high-risk (t(4;14), del(17p13) or complex) ( Supplementary Table 1 summarizes demographics and pretransplant characteristics). Peripheral blood mononuclear cells obtained by steady-state apheresis were transduced with lentiviral vector encoding the affinity-enhanced NY-ESO c259 TCR and expanded using paramagnetic microbeads conjugated to antibodies to CD3 and CD28. After autologous stem cell collection, patients were conditioned with highdose melphalan (140-200 mg per square meter of body surface area (mg/m 2 )) and then received autologous stem cell infusion 2 d later. On day 2 after stem cell transplantation, patients received a mean of 8 billion CD3 + T cells (range 1-10 billion) with an average transduction efficiency of 33% (range 18%-49%). We infused a mean of 2.4 billion (range, 0.45-3.9 billion) NY-ESO c259 -engineered CD3 + T cells, which comprised >90% L-selectin (CD62L)-expressing cells and a variable percentage of CD4 + and CD8 + T cells ( Supplementary Table 2 ).
T cell persistence, trafficking and function
We evaluated T cell expansion, persistence and trafficking to marrow by a qualified quantitative reverse-transcription PCR (qRT-PCR) assay. Peak numbers of engineered T cells were detected at study day 14, and median persistence per microliter of blood was 104 (range, 16-741), 489 (range, 63-1,850), 107 (range, 3-881) and 51 (range, 1-237) at days 7, 14, 28 and 42 after ASCT, respectively ( Fig. 2a) . Peak percentages of engineered cells in leukocytes were found on day 7 (median 47%; range 10-80%), during the white blood cell nadir (Fig. 2b) , and declined thereafter to a median of 3% (range <1-11%) and 1% (range <1-9%) on days 28 and 180, respectively.
A subset of patients (13/20) underwent marrow biopsies at multiple time points after transplant; engineered cells were detected in marrow from day 7 to day 180 (Fig. 2c) . The near 100% marking in marrow biopsy at day 7 was inconsistent with flow cytometry and histochemistry and was higher than in blood. This suggests enrichment of gene-marked cells at the site of antigen (marrow) and may be due in part to preferential infiltration of marrow with engineered cells containing multiple integration events. These data suggest that multiple integration events may improve T cell reactivity to the targeted antigen. A majority of patients (15/20) Fig. 2) . NY-ESO c259 T cells were detected by dextramer staining in blood and marrow through 2 years of follow-up ( Supplementary Fig. 3 ). Of 10 patients who reached 2 years of follow up, 9 continued to have detectable engineered cells in the peripheral blood ( Supplementary  Table 3 ). Serum cytokine analysis was done for all patients. A significant elevation of IL-6 (baseline versus day 7, P = 0.001) was detected in all patients (median increase, 22-fold; range, 8-to 2,272-fold) within 7-28 d after infusion, which overlapped with the period of maximum T cell expansion ( Supplementary Table 4 ). Four responding patients with high levels of engineered T cells were evaluated by flow cytometry for production of cytokine IFN-γ and cytotoxic potential (as indicated by production of granzyme B production and surface expression of lysosome-associated membrane protein 1 (CD-107a)) in response to peptide-loaded targets. These data show that polyfunctional T cells that were generated during manufacturing were engrafted in the patients and remained functional in the blood for up to 1 year after infusion ( Fig. 2d) .
Immunohistochemical analysis of marrow from one of four patients who had day 7 marrow biopsies demonstrated that residual CD138 + myeloma was associated with CD8 + T cell infiltration ( Fig. 3a) . A substantial fraction of the infiltrating CD3 + cells (11.2%) were engineered ( Fig. 3b) . As per protocol, patients who relapsed with NY-ESO-1 or LAGE-1 antigen-positive disease were permitted to receive a second gene-modified T cell infusion without a second ASCT. In one case (patient 253) the marrow was densely packed with CD138 + myeloma cells before the second infusion. CD138 + myeloma npg cell numbers decreased at day 24 after reinfusion in association with an increase in CD8 + T cells in that compartment. Low-dose lenalidomide (10 mg/day) was started on day 24. Two weeks later, on day 38, the marrow biopsy showed a considerable increase in the abundance of CD8 + T cells concomitant with a marked decrease in marrow plasmacytosis with extensive CD138 + myeloma cell necrosis ( Fig. 3c and Supplementary Fig. 4) . Notably, although engineered T cells were detected in marrow at day 38, deep-sequencing-based TCR spectratyping of marrow biopsies revealed the presence of two dominant TCR clonotypes that were distinct from the clonotype (Vβ13.1) expressed by the NY-ESO c259 engineered cells ( Supplementary  Fig. 4 ). Collectively, these results suggest that specific anti-myeloma T cell activity, mediated by infusion of engineered autologous T cells and potentially enhanced by immunomodulatory treatment with lenalidomide, may result in antigenic spreading and the development of a secondary endogenous antitumor immune response. A representative example of the myeloma tumor targeting that we observed in patients with advanced and refractory disease is provided by the clinical course of patient 250. This 72-year-old patient had a prior ASCT with a 2-year response duration, after which he relapsed with a high-risk t(4;14)(p16.3;q32.3) translocation. After additional treatment (with both bortezomib and lenalidomide), he developed progressive disease with high serum concentrations of free κ-light chains, extensive osteolytic bone lesions associated with large adjacent soft tissue masses and a biopsy-proven pancreatic plasmacytoma. He attained a stringent complete response (CR) ( Fig. 4a) , accompanied by expansion and then durable persistence of engineered T cells in marrow and blood, with approximately 1% of CD3 + lymphocytes expressing the transgenic receptor at 1 year ( Fig. 4a,b ). This expansion and persistence was accompanied by normalization of marrow and clearance of the pancreatic plasmacytoma ( Fig. 4c,d) . The patient later relapsed, and at relapse developed progression in the abdominal mesentery and pelvic soft tissue. Notably, the patient's marrow remained free of myeloma cells, and expression of NY-ESO-1 and LAGE-1 was absent until his death from disease progression at 2 years after infusion of engineered T cells, suggesting ongoing Data from four responding patients with durable persistence are shown for the manufactured product (MP), and from day 21 (d21) to d360 after infusion.
Figure 3 Tumor and T cell infiltration in marrow.
Core marrow samples were collected from patient 258 at day 7. (a) Marrow was stained for the plasma cell marker CD138, which is expressed on normal plasma and myeloma cells, and for CD8 to evaluate T cell infiltration. (b) Mononuclear cells were isolated from fresh marrow aspirates and stained with anti-CD3 antibody to detect T cells, and with dextramer reagent specific for NY-ESO TCR c259 peptide and HLA-A2 to detect gene-modified cells.
The dextramer fluorescence minus one (FMO) is shown as a negative control. Gene-modified cells in the controls and test panel are denoted by the box, and the number to the left of the box represents the overall percentage of cells from the CD3 + fraction. (c) Patient 253 received a second infusion of NY-ESO c259 TCR T cells in the absence of ASCT after progressing following ASCT and first infusion. Core marrow biopsies were collected just before infusion and at day 24 and 38 after infusion and were stained for the CD138 plasma cell and myeloma tumor marker, and for CD8 T cell infiltration. Scale bars, 20 µm (a,b). npg immune surveillance and antigen escape. Of note, the gene-modified T cells isolated from this patient showed polyfunctionality and cytotoxic potential that persisted for at least 1 year after infusion.
Evidence for NY-ESO-1 and LAGE-1 tumor antigen targeting
To evaluate antigen-specific antitumor activity of the engineered T cells, we performed qRT-PCR analysis on marrow specimens collected from patients and quantitatively assessed transcript levels for NY-ESO-1 and LAGE-1, as well as CD138 as a measure of myeloma or plasma cell burden. We observed a loss, relative to levels at enrollment, of NY-ESO-1 and LAGE-1 transcripts in 12/15 patients at day 100 and in 11/13 at day 180. At day 100, 3/15 patients had detectable levels of NY-ESO-1 and LAGE-1 transcripts, an observation that accompanied a drop of engineered cells in the peripheral blood to very low or undetectable levels and preceded relapse in two cases ( Fig. 5) . Four patients had an increase in CD138 transcripts in the absence of NY-ESO-1 and LAGE-1 transcripts, suggesting that the treatment potentially selected for tumor escape subclones that lacked target tumor antigen. Patients 256 and 212 were confirmed as having complete responses, despite higher amounts of CD138 transcripts, which may reflect polyclonal plasma cell recovery. Taken together, these data suggest induction of robust and, in a subset of patients, persistent tumor antigen-specific immune responses. The data on two patients (252 and 260) who had aggressive relapsed and refractory disease before study treatment are also instructive with respect to antigen-specific targeting (Supplementary Note). These patients had partial myeloma responses after ASCT and NY-ESO c259 T cell infusion, which were ongoing at 2 years and 9 months, respectively, without lenalidomide maintenance. Serial follow-up examinations of bone marrow showed that the residual myeloma cells were negative for NY-ESO-1 and LAGE-1 (as assessed by PCR), suggesting that the engineered T cells selectively eliminated the antigen-positive myeloma fraction that may have been responsible for the more aggressive clinical courses that were observed in these patients before transplant. Additional details on these two patients are provided in the Supplementary Note.
Clinical outcomes
There were no treatment-related fatalities. All seven serious adverse events resolved ( Supplementary Table 5 ). We observed 17 adverse events that were probably related to the treatment, all of grade 3 or lower ( Supplementary Table 6 ). Skin rash with lymphocytosis occurred in 3/20 patients. Some patients had a diarrheal syndrome that occurred later than expected for melphalan-induced mucositis and was confirmed in 3/20 patients to be autologous graft-versus-host disease (aGVHD) (Supplementary Fig. 5 ). Analysis of engineered T cells in inflamed and normal colonic tissue and peripheral blood was performed in patients who developed aGVHD. Although engineered T cells were present in inflamed tissue, they were proportionately lower at sites of inflammation than in adjacent noninflamed tissues, suggesting that they were not driving the event ( Supplementary  Table 7 ). Furthermore, we have previously observed aGVHD in the gut and skin after post-ASCT adoptive transfers of activated but non-gene modified T cells 14 .
We estimated overall survival (OS) and progression-free survival (PFS) functions using the Kaplan-Meier method (Fig. 6a,b) . With a median follow-up of 21.1 months (corresponding 95% confidence interval (CI): 12.7-22.9 months), 10/20 patients (50%) were alive and progression-free, 15/20 (75%) patients were alive and 5/20 (25%) died after disease progression. All 20 patients were assessed for clinical npg response at day 100, which was before lenalidomide maintenance was received by a subset of patients ( Supplementary Table 1 ).
Of the 20 patients, 14/20 (70%) patients had a near complete response (nCR, defined as myeloma monoclonal band detectable only by sensitive immunofixation assay) or a CR, and 2 patients had a very good partial response (VGPR; ≥90% reduction in paraprotein levels), 2 had a partial response (50-90% reduction), 1 had stable disease (<50% reduction) and 1 had progressive disease. Nine patients experienced gradual improvements in tumor markers and/or disease response between the first and second disease assessment at day 100 ( Supplementary Fig. 6) , which is consistent with delayed immunemediated antitumor effects as reported in other trials 38 Fig. 7) . A swimmer plot shows the duration and depth of response for each patient, and associated levels of T cell persistence at major time points (Fig. 6c) . Progression in eight of ten cases correlated with a loss of persisting gene-modified cells in the peripheral blood, and the myeloma was antigen-positive upon relapse. In no cases was an antigenpositive tumor relapse observed in the presence of engineered cells persisting at ≥6 cells per microliter in blood ( Supplementary  Table 8 ); as noted above, two patients relapsed with NY-ESO-1-and LAGE-1-antigen-negative subclones.
We estimated the association of LAGE-1, NY-ESO-1, CD138 and T cell persistence in the blood using mixed-effects modeling. Notably, there was a significant (P = 0.014) inverse correlation between target antigen levels and gene-modified T cells. Between days 0 and 180 after transplant, the T cell persistence in blood was inversely correlated with the level of NY-ESO-1 expression in the marrow (P = 0.022) and marginally inversely correlated with LAGE-1 expression (P = 0.098) ( Supplementary Table 9 ). In contrast, there was no relationship over time between T cell persistence in blood and CD138 expression in marrow.
Inferences about patients' survival experience were made on the basis of the joint modeling for longitudinal and time-to-event (OS and PFS) data. The statistical model revealed that baseline levels of NY-ESO-1, LAGE-1, CD138, cytogenetic abnormalities, engineered cell dose, prior ASCT status and age did not affect OS. T cell persistence in neither blood nor marrow was predictive of OS. However, longitudinal expression of NY-ESO-1 and LAGE-1 was associated with OS, and the corresponding P values for their effects in the model are 0.037 and 0.055, respectively. There was a marginal effect of CD138 expression (P = 0.110). All three biomarkers had positive coefficients (estimated by the joint model); hence, the hazard of death increases with a higher level of these biomarkers ( Supplementary Table 10 ).
PFS was also jointly modeled with time-changing biomarkers, and the results were concordant with the OS results. The NY-ESO-1, LAGE-1 and CD138 levels may be predictive of the time to progression, but the P values did not reach significance, with values of 0.094, 0.065 and 0.160, respectively, for PFS ( Supplementary Table 11 npg LAGE-1 and CD138 levels in the marrow were more pronounced in OS than in PFS but followed the same pattern in both. Higher levels of these markers over time may predict a worse prognosis.
DISCUSSION
We show in this study that infusion of ex vivo-expanded NY-ESO c259 TCR-engineered T cells was well-tolerated without significant safety concerns and that engineered T cells expanded in vivo, trafficked to disease tissue, persisted and showed durable target-specific antitumor activity. The observation of safety is notable and may be related to physiological signaling and antigen specificity provided by the TCR. In contrast, T cells engineered to express a CD19-directed CAR have been associated with severe adverse events attributable in part to CRS of grade 3 or higher 39 , an IL-6-mediated macrophage activation syndrome 40 or sepsis 41 . Complications associated with CRS or neurotoxicity have led to deaths in the CD19 CAR studies 42 . Severe CRS did not occur in our study, despite the detection of elevated levels of IL-6. These levels were comparable to what has been observed in CD19 CAR T cell studies for patients without severe CRS but are generally lower than the peak levels measured for patients who developed severe CRS 21 . It is important to note that a constellation of post-ASCT adverse events may mask clinical diagnosis of mild cases of CRS. In other solid tumor NY-ESO c259 T studies we have observed multiple cases of mild CRS 43 . High antigen burden may increase the risk of CRS for both CAR and TCR approaches. However, a potential risk that may be unique to engineered TCRs is enhanced recognition of non-target peptides, as observed in a prior study in which the wild-type and affinity-enhanced TCR recognized a contractile protein in cardiac tissue 44, 45 .
Persistence of engineered T cells and trafficking to tumor sites are increasingly being reported as biomarkers predictive of clinical responses 46 , and durable persistence may be important to maintain clinical responses in at least a subset of patients. Previous studies with engineered T cells have not demonstrated persistence and expression beyond 1 month 26, 30 . In this study, long-term persistence was detectable in a majority of patients, and continued expression of the TCR was observed up to 2 years after infusion, which suggests that significant gene silencing was not occurring, in contrast to clinical data on retroviral vector-based gene transfer 26, 47 . Notably, this is the first published study of lentiviral vector-mediated TCR gene expression in humans. Additionally, the method of T cell manufacturing, which selects for younger T cells and prolonged expansion, is probably an important factor in durable persistence 48 , and studies using CAR-modified T cells have demonstrated similar durations of persistence in oncology and HIV clinical studies 21, 49 . We also observed robust trafficking to marrow, the principal site of tumor. Relapse was associated with a loss of gene-modified T cells, which suggests that methods for sustaining long-term persistence of engineered T cells in a larger fraction of patients may improve treatment durability.
Several lines of evidence support on target activity of the engineered T cells. First, expression levels of NY-ESO-1 and LAGE-1 decreased in all patients after transplant, with progressive improvement over time in a subset, and remained very low except in those patients who had loss of gene-modified T cells. Second, a subset of patients with partial responses exhibited only antigen-negative myeloma after treatment, and another subset of patients developed antigen-negative myeloma on relapse. Third, expression of NY-ESO-1 correlated inversely and significantly to higher numbers of engineered T cells, whereas no association of T cell persistence with CD138 expression (more reflective of burden of normal plasma cells and/or antigennegative myeloma cells) was observed. Future approaches should consider targeting more than one antigen to avoid emergence of antigen escape variants and allow treatment of patients presenting with NY-ESO-1-and LAGE-1-negative tumors. Targeting more than one tumor antigen combined with the development of tumor-specific TCRs restricted to additional common HLA antigens should enable this therapy to be available to most patients.
In this study 70% of patients achieved nCR or CR, which compares favorably with the expected response frequencies following ASCT or double-sequential (tandem) ASCT, where response rates are typically <40% in patients without high-risk disease 50, 51 . This is encouraging, given the predisposition of patients on our study to worse outcomes owing to an enrollment requirement for high-risk or advanced disease, a considerable frequency of prior ASCT and the known association of cancer-testis antigen expression with poor prognosis. Notably, LAGE-1 expression was identified by microarray analysis to correlate with bortezomib resistance 52 . In our small data set, we observed a significant inverse association between expression of LAGE-1 and NY-ESO-1 mRNA expression over time and OS. It must be acknowledged that the use of high-dose chemotherapy in our 260  259  212  258  257  256  211  210  209  255  202  207  254  206  204  253  252  201 npg trial, as with lymphodepleting chemotherapy in virtually all trials of gene-modified T cells, makes it difficult to rigorously ascribe clinical activity to the NY-ESO-TCR-T cells without a randomized study. Taken together, our data support the continued development of NY-ESO-1-and LAGE-1-TCR-engineered T cells for treatment of myeloma and suggest that methods for enhancing long-term survival and function of the cells may improve treatment durability. Such strategies may include repeat infusions and/or incorporation of immune-modulatory agents such as checkpoint inhibitors and maintenance lenalidomide [53] [54] [55] . The striking clinical response that occurred in patient 253 after the second infusion of T cells in concert with the emergence of nontransduced T cell TCR clonotypes suggests that such approaches may also induce secondary tumor-specific immune responses to myeloma through antigen spreading. Future strategies to augment antigen spreading to cancer neoantigens may further enhance durable clinical activity 56 .
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINE METHODS
Study design. The clinical study is registered at ClinicalTrials.gov (NCT01352286). Briefly, the study is a phase I/IIa single-arm trial that enrolled 24 patients, 20 of whom received ASCT followed by gene-modified T cells. On the basis of published data 50 the expected nCR/CR rate following first ASCT in patients without high-risk disease was estimated to be 36% 50 . We hypothesized that the CR rate in this trial would be 66% (2/3 patients). Using the one-sided Chi-square test, we had 85.8% power to detect this difference at a significant level of 5%.
Fourteen patients (70%) were self-reported Caucasian or of European descent, and 6 patients (30%) were African American or Hispanic. Ten patients (50%) were female, and the median age at enrollment was 59 (range: . Patients were required to have symptomatic myeloma with active and/or high-risk disease and adequate cardiac, renal and pulmonary function. Patients in complete remission were excluded unless they had high-risk cytogenetics. Patients received a median of 3 lines of prior therapy (range: 1-5); 5 patients (25%) had relapsed after an earlier ASCT. Twelve patients (60%) had cytogenetic abnormalities including 7 (35%) with confirmed high-risk abnormalities (t(4;14), del(17p13), complex). Administration of lenalidomide (10 mg/day) was recommended starting at day 100 after transplant.
To be eligible for the treatment phase, HLA-A*0201-positive patients first consented to a marrow examination to obtain myeloma cells to test and confirm NY-ESO-1 or LAGE-1 expression by RT-PCR. All participants gave written informed consent in accordance with the Declaration of Helsinki. Study approval was obtained from the Institutional Review Boards (IRBs) of the University of Maryland and the University of Pennsylvania, the US Food and Drug Administration (FDA) and the NIH Recombinant DNA Advisory Committee (RAC).
A flow diagram depicting the trial design is shown (Fig. 1) . Briefly, after confirmation of HLA-A*0201 status and expression of NY-ESO-1 or LAGE-1 in the myeloma cells, patients received an intramuscular injection of Prevnar-13-the pneumococcal conjugate vaccine (PCV)-into the nondominant deltoid muscle. PCV served as a marker of antigen-specific immune reconstitution. About 10 d after this immunization all patients had steady-state apheresis to collect approximately 1 × 10 8 mononuclear cells per kilogram of body weight. Patients proceeded to stem cell mobilization using cyclophosphamide at a dose of 1.5-3.0 g/m 2 followed by G-CSF (10 µg/kg).
Approximately 4 weeks after the apheresis, patients received high-dose therapy with melphalan (200 mg/m 2 or 140 mg/m 2 if age >70 years) followed by infusions of autologous stem cells (≥2 × 10 6 CD34 + cells/kg body weight) at day 0. The engineered T cells were infused on day 2. Supportive care measures included antibiotic prophylaxis and administration of G-CSF starting on day 5. Three additional pneumococcal conjugate vaccine immunizations (Prevnar-13) were given at days +14, +42 and +90. Lenalidomide maintenance at 10 mg per day was started at day 100 after transplant for patients with sufficient marrow recovery (a total of 13/20 patients received maintenance lenalidomide for at least 3 months). Optional bone marrow aspirates for assessment of T cell trafficking were collected at days +7, +21, +42, +100 and +180 after transplant.
Clinical response assessments. Myeloma assessments were performed at days +42, +100, +180 and every 3 months thereafter while patients remained on study. Disease response was assessed in accordance with the International Uniform Response Criteria for myeloma assessment 57 with the additional category of near complete response (nCR) defined as disease that is detected only by immunofixation, less than 5% plasma cells in the marrow, and no increase in size or number of lytic bone lesions. This method of assessment is consistent with the methods employed by the Bone Marrow Transplantation Clinical Trials Network at the time of the conduct of this study and is consistent with methods used in recently published studies. The category of nCR is relevant to studies of adoptive T cell therapy where the early immune reconstitution can lead to oligoclonal banding that can confound accurate assessment of disease clearance 58 .
Cell manufacturing. Engineered T cells were manufactured initially at the Cell and Vaccine Production Facility at the University of Pennsylvania (Philadelphia, PA), and later the process was transferred to a commercial contractor, Progenitor Cell Therapy (PCT, Allendale, NJ). Comparability studies were conducted and submitted to the Food and Drug Administration to demonstrate comparability of the product at PCT. Engineered T cells were manufactured from CD25 depleted CD4 and CD8 T cells that were activated and expanded using anti-CD3-CD28 antibody-conjugated paramagnetic microbeads (Life Technologies, Carlsbad, CA) as previously described 48 . T cells were transduced at a multiplicity of infection of 1 transducing unit (TU) per cell. The manufacturing process took 9-12 d, and an additional 7-10 d were required to complete release testing. An overview of the process is shown in Figure 1b .
Vector. The lentiviral vector is a self-inactivating vector derived from HIV-1 (ref. 59 ) and containing the WPRE element. The transgene is expressed off of the EF1α promoter. Lentiviral vector was produced at the City of Hope (Duarte, CA) using transient transfection with four plasmids expressing the transfer vector, Rev, VSV-G and gag/pol, in 293T cells. Supernatant was collected at multiple time points, clarified, treated with benzonase, and concentrated by tangential flow filtration and centrifugation. Transduction potency was measured on primary T cells.
Assays for NY-ESO-1 and LAGE-1 expression and persistence, trafficking and function of gene-modified T cells.
Research sample processing, freezing, and laboratory analyses were performed in the Translational and Correlative Studies Laboratory at the University of Pennsylvania, which operates under principles of Good Laboratory Practice with established SOPs and/or protocols for sample receipt, processing, freezing and analysis. Assay performance and data reporting conforms with MIATA guidelines 60 . Toward the end of the study, assays were transferred to Cambridge Biomedical (Cambridge, MA), a commercial laboratory also operating in compliance with Good Laboratory Practices.
Sample draws and processing. Samples (peripheral blood, bone marrow) were collected in lavender top (K 2 EDTA,) tubes (Becton Dickinson). Samples drawn at the University of Pennsylvania were delivered to the laboratory within 2 h of draw; samples drawn at the University of Maryland were delivered to the laboratory by overnight shipment at room temperature and in insulated containers. Samples were processed within 30 min of receipt according to established laboratory SOPs. Peripheral blood and marrow mononuclear cells were purified, processed and stored in liquid nitrogen.
qPCR analyses. Whole-blood samples were collected in lavender top (K 2 EDTA) BD vacutainer tubes (Becton Dickinson). Genomic DNA was isolated from whole blood or marrow using QIAamp DNA blood midi kits (Qiagen) and established laboratory SOPs, quantified by spectrophotometer and stored until testing at −80 °C. qPCR analyses were performed in bulk using ABI Taqman technology and a validated assay to detect the WPRE sequence present in the lentivirus backbone, using 200 ng genomic DNA per time-point for peripheral blood and marrow samples and using the methodology described 61 including normalizing for amplification of input DNA using amplifications with the CDKN1A primer/ probe set (NF). The WPRE primers were as follows: 5′ WPRE.227. Forward: 5′ CGCAACCCCCACTGGTT 3′ (nt 227-244 of the WPRE gene) an antisense primer with the sequence: WPRE.289.R: 5′AAAGCGAAAGTCCCGGAAA 3′ (nt 270-289 of the WPRE gene). These primers amplify a 62-nt long sequence from the WPRE coding sequence that can be detected using the FAM labeled probe 5′ FAM-TTGCCACCACCTGTC 3′. Calculated values were adjusted by a factor of 0.5 (EF) to account for amplification efficiency of this primer-probe combination and on the basis of flow-cytometric analysis of the infused cell product. Values from this analysis are reported as average transgene copies per cell, calculated as: average transgene copies/cell = copies plasmid detected by qPCR/input DNA (ng) × 0.0063 ng DNA/cell × CDKN1A NF × EF. The limit of detection for the assay is <50 copies/µg genomic DNA. The white blood cell count was used as an amplifier to calculate the number of gene modified cells in the blood. An assumption of 1 vector copy per cell was assumed based upon the multiplicity of infection of 1 used for cell transduction; however, the gene modified cell population is likely to contain subset of cells with multiple integration events.
RT-qPCR analysis. Total RNA was isolated directly from whole marrow using Ribopure TM blood kits (Ambion), and cDNA synthesis was performed using iScript cDNA synthesis kits (Bio-Rad). cDNA was used directly in qPCR assays to detect and quantify the relative abundance of LAGE-1 (Hs00535628_m1), NYESO-1 (Hs00265824) and CD138 (Hs00896423_m1) transcripts, using the npg
